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Background: In asthma, cysteinyl leukotrienes (CysLTs) play varying roles in the bronchomotor
response to multiple provocative stimuli. The contribution of CysLTs on the airway’s response
to hypertonic saline (HS) inhalation in asthma is unknown. Whether polymorphisms in the
leukotriene biosynthetic pathway affect the contribution of CysLTs to this response is also
unknown.
Methods: In a prospective, randomized, double-blind, placebo-controlled cross-over study,
mild and moderate asymptomatic asthmatics underwent inhaled 3% HS challenge by doubling
the duration of nebulization (0.5, 1, 2, 4, and 8 min) 2 h after one dose of montelukast (a CysLT
receptor 1 [CysLTR1] antagonist) or placebo, and after three-week courses. We examined the
effect of the leukotriene C4 synthase (LTC4S) polymorphism (A-444C) on the efficacy of mon-
telukast against HS inhalation in an exploratory manner.
Results: In 37 subjects, 2 h after administration of montelukast, the mean provocative dose
of HS required to cause a 20% drop in FEV1 (HS-PD20) increased by 59% (9.17 ml after
placebo vs. 14.55 ml after montelukast, p Z 0.0154). Three weeks of cysLTR1 antagonism
increased the HS-PD20 by 84% (10.97 vs. 20.21 ml, p Z 0.0002). Three weeks of CysLTR1
antagonism appeared to produce greater effects on blocking bronchial hyper-responsive-
ness (2 h vs. three-week HS-PD20 values 14.55 vs. 20.21 ml respectively, p Z 0.0898). We
did not observe an effect of the LTC4S polymorphism on the response to CysLTR1 antago-
nism in this cohort.
Conclusions: A significant proportion of HS-induced bronchoconstriction is mediated by
release of leukotrienes as evidenced by substantial acute inhibition with a CysLTR1riene; CysLTR1, cysteinyl leukotriene receptor 1; FEV1, forced expiratory volume in 1 s; HS, hyper-
thase; PD20, provocative dose of hypertonic saline required to decrease FEV1 by 20%.
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668 S. Kazani et al.antagonist. There was a trend toward greater inhibition of bronchial responsiveness with
three weeks of therapy as opposed to acute CysLTR1 antagonism.
Clinicaltrials.gov registration number NCT00116324.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory disorder characterized by
reversible obstruction of the airways. Bronchial hyper-
responsiveness to inhaled stimuli is a characteristic feature
of asthma. Direct stimuli such as methacholine lead to
bronchoconstriction predominantly by their action on
effector cells such as airway smooth muscle. In contrast,
indirect stimuli such as exercise, and inhalational chal-
lenges with adenosine, cold air, and hyperosmolar aerosols
including mannitol and hypertonic saline provoke bron-
chospasm via the release of mediators from inflammatory
cells.1,2 Cysteinyl leukotrienes, prostaglandins, histamine
and acetylcholine are some of the mediators implicated in
the pathophysiology of bronchoconstriction caused by
indirect challenges in asthma.1 Cysteinyl leukotrienes
(CysLTs, which include LTC4, LTD4 and LTE4) are arachidonic
acid derived biologically active mediators of inflammation.3
Upon release by resident and inflammatory airway cells,
they activate CysLT receptor 1 (CysLTR1) which leads to
initiation and amplification of a variety of patho-physiologic
changes observed in asthmatic airways, including eosino-
phil recruitment, stimulation of mucus secretion, bronchial
smooth muscle contraction and airway edema.4 CysLTR1
blockers such as montelukast antagonize the effects of
CysLTs at this receptor and have been shown to be effica-
cious in asthma.5,6 Montelukast is specifically helpful
against exercise and allergen-induced bronchial hyper-
responsiveness.7e9 The role of CysLTs and leukotriene
modifying drugs including LT receptor antagonists and
5-lipoxygenase inhibitors have been studied extensively in
most indirect bronchoprovocative challenges in
asthma.2,10e13 Their role in hypertonic saline (HS) induced
bronchospasm is suggested by elevated urinary LTE4 after
HS inhalation.14 However their quantitative contribution
and thus their significance in an airway’s bronchomotor
response to inhalation of HS is unknown.15
To determine whether CysLTs play a significant role in
HS-induced airway narrowing in asthma, we examined the
effect of a single dose of montelukast, a CysLTR1 antago-
nist, in inhibiting the response to HS. Since CysLTs can also
mediate a variety of patho-physiologic inflammatory events
that occur in asthma including eosinophil recruitment,
stimulation of mucus secretion, and airway edema,4 we
also examined whether prolonged therapy would amplify
the efficacy seen after a single dose.
In addition to potential stimuluseresponse heteroge-
neity, we also examined whether genetic heterogeneity
might affect the role CysLTs play in mediating airway
responses by examining the difference in protection
conferred by a CysLTR1 antagonist in a genotype-stratified
manner. A single nucleotide polymorphism in the promoter
region of a gene which is involved in CysLT synthesis, LTC4
synthase (LTC4S A-444C), has been associated with anincrease in CysLT production.16 The dominant variant C
polymorphism has also been associated with increased
effectiveness of CysLTR1 antagonism against bronchocon-
striction in asthma17 and a reduced risk for asthma exac-
erbations.18 In contrast to polymorphisms in other genes
involved in leukotriene synthesis/receptor pathways, this
one has been most extensively examined for its effect on
clinical outcomes after therapy with leukotriene antago-
nists. In an exploratory manner, we examined whether this
particular polymorphism modulated the efficacy of mon-
telukast against HS-induced bronchospasm. We included
this pharmacogenetic component into the clinical trial in
a prospective, double-blind placebo-controlled cross-over
study design, which has not been done in the past.
Methods and materials
Subjects
The protocol received IRB approval from our institutional
review board and written informed consent was obtained
from all participants. Subjects had to be between 18 and 65
years old, and diagnosed with mild or moderate asthma by
their physicians prior to enrollment in the study. They had
to be off all controller medications such as inhaled corti-
costeroids, long acting beta agonists and leukotriene
receptor antagonists for at least four weeks, with
FEV1  60% of the predicted value at the baseline visit.
Subjects were required to demonstrate hyper-responsive-
ness to HS with a baseline PD20  18 ml to be eligible for
analysis. A cut off of 18 ml was set pre hoc to enable us to
detect a 100% increase (doubling dose) in the amount of HS
tolerated after randomization, as 36.82 ml of HS were
inhaled during the last stage of the challenge. Exclusion
criteria included smoking history 10 pack-years or any
cigarette use within the last 12 months, respiratory tract
infection within the last six weeks, and asthma exacerba-
tion within the last four weeks of study enrollment. We
consented 136 subjects who were found to be eligible by
these screening criteria.
Study design
We conducted a prospective, randomized, double-blind,
placebo-controlled, cross-over study. After obtaining
baseline PD20 to HS at the screening visit, eligible subjects
were randomized as depicted in Fig. 1. At visit two,
subjects were challenged with HS 2 h after receiving one
oral dose of blinded drug (montelukast [Singulair, Merck &
Co., Inc, USA] 10 mg dose or matching placebo). Subse-
quent to a washout period of at least one week, subjects
were re-challenged 2 h after receiving the alternate study
drug at visit three. Subjects returned for a repeat challenge
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Figure 1 Study design. M Z montelukast, P Z placebo, HS Z hypertonic saline challenge.
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Figure 2 Subject enrollment.
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same study medication which they received at visit three
(montelukast or placebo). They then entered a minimum
four week washout phase following which they returned at
visit five to repeat a baseline spirometry and receive the
alternate study medication. Subjects returned thereafter
at visit six after taking this medication for at least three
weeks. The order of study medications was determined by
random allocation in blocks of two by the investigational
pharmacy.
Hypertonic saline challenge
3% HS was administered for inhalation through a DeVilbiss
Ultraneb 99 nebulizer via a protocol of doubling duration of
exposure from 30 s to 8 min. The result of the inhalation
challenge was measured as HS-PD20, i.e. provocative dose
of HS in ml required to cause a 20% drop in FEV1. PD20 was
calculated by logarithmic interpolation of the amount of
saline delivered. When the drop in FEV1 was <20% at the
end of the 8 min inhalation, the PD20 was assigned a value
of twice the amount of saline inhaled during the last step,
i.e.73.64 ml.
Sample collection and genotype analysis
Genomic DNA was extracted from whole blood by the
PureGene DNA Purification system (Qiagen, Valencia, CA).
The LTC4S gene promoter polymorphism rs730012 was
genotyped using either Sequenom MassARRAY system
(Sequenom, San Diego, CA) or Taqman analysis on the
Applied Biosystems 7900HT system (Applied Biosystems,
Forster City, California, USA) based on assay availability in
the laboratory. Quality control was assured by running
internal and external controls on all genotyping plates.
Statistical analyses
Sample size was determined a priori to be 14 in each
genotype group (A homozygotes and C allele carriers) to
have 80% power to detect a doubling dose difference in
PD20 after receiving montelukast compared to that after
receiving placebo at a 95% significance level. In the
manuscript, PD20 data are presented as geometric meanswith the 95% confidence intervals in brackets. We used
Student’s t-tests to compare normally distributed data,
Wilcoxon rank sum tests for unpaired non-parametric data
and Wilcoxon signed rank tests for paired non-parametric
data. Categorical data were analyzed using two-sided
Fisher’s exact tests. Data were analyzed using SAS 9.1 (SAS
Institute Inc., Cary, NC, USA) where the significance level is
set at 95%.
Results
Subject enrollment
136 mild to moderate asthmatics using only rescue inhaler
on an as-needed basis signed informed consent between
April 2003 and September 2006 (Fig. 2). Ninety one (67%) of
these subjects did not qualify to continue the study as they
were unresponsive to the 3% HS challenge. Further tests to
confirm their diagnosis of asthma were not conducted prior
to their exit from the study. Five subjects were excluded
prior to analysis because they were unresponsive to HS
inhalation at all visits subsequent to screening. Three
subjects were unable to complete sufficient study visits to
be included in comparative analysis. Of the 37 subjects thus
included in data analysis, two dropped out after visit three
(one in each genotype group); one due to an asthma
exacerbation unrelated to study medications or proce-
dures, and the other due to unknown reasons. Their avail-
able data have been included in the results below. Table 1
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Figure 3 a. Difference in HS-PD20 2 h after a single dose of
study medications. Horizontal bars represent geometric
means, 9.17 ml (95% CI 6.65e12.65 ml) and 14.55 ml
(9.87e21.46 ml) respectively. NZ 37. b. Difference in HS-PD20
after three-week courses of study medications. Horizontal bars
represent geometric means, 10.97 ml (95% CI 7.36e16.35 ml)
and 20.01 ml (13.15e31.06 ml) respectively. N Z 35.
670 S. Kazani et al.presents their baseline demographics and genotype-specific
data.
Change in lung function after CysLTR1 antagonism
The mean post-drug baseline FEV1 was similar during
placebo and montelukast visits, both 2 h after one dose
(both 86%), and after three-week courses (84 vs. 86%,
p Z 0.48). The post-drug FVC was similar as well (90 vs.
91%, pZ 0.61 2 h after one dose; 89 vs. 87%, pZ 0.61 after
three-week courses). There was no change in post-drug
FEV1 or FVC (after both placebo and montelukast and after
both one dose and three-week courses) when compared
with baseline established at visit 1, either.
Change in HS-PD20 after CysLTR1 antagonism
Acute CysLTR1 antagonism (2 h after administration)
increased the PD20 by 59% (9.17 [95% CI 6.65e12.65] after
placebo vs. 14.55 [9.87e21.46] ml after montelukast,
p Z 0.0154) (Fig. 3a).
Three weeks of CysLTR1 antagonism over three weeks
increased the PD20 by 89% (10.97 [7.36e16.35] after
placebo vs. 20.21 [13.15e31.06] ml after montelukast,
p Z 0.0002) (Fig. 3b).
There was a trend towards statistical significance in the
difference between the mean PD20 after a single dose of
montelukast vs. that after a three-week course (14.55
[9.87e21.46] ml vs. 20.21 [13.15e31.06], p Z 0.0898).
There was no period effect of the order of study medica-
tions on outcomes.
Genotype-specific response
Seventeen subjects were homozygous for the A allele while
19 carried at least one copy of the C allele. Since only two
of the 19 C allele carriers were homozygous for the C allele,
we combined the AC and CC genotypes into one group
labeled as the “variant C allele carriers”, similar to how this
rare genotype has been handled in previous studies.18,19 ATable 1 Characteristics of study subjects.
All subjects A homo
N 37 17a
Age (yr) 30  10 (18e57) 32  12
Sex (% female) 51 65
Race (% Caucasians) 73 53
Ethnicity (% Hispanic) 11 6
FEV1 (L) 3.26  0.83 (1.63e4.86) 3.00 
FEV1 (% pred) 87  13 (61e115) 86  15
FVC (L) 4.37  1.08 (2.44e6.75) 4.05 
FVC (% pred) 98  14 (69e134) 97  16
Baseline PD20 to HS
inhalation (ml)b
7.45 (5.88e9.44) 7.81 (5.
Data presented as mean  SD (range) unless otherwise noted.
*p value is for difference between A homozygotes and C allele carrie
a Sum not equal to 37 because one subject could not be successfull
for the C allele.
b Data presented as geometric mean (95% CI).blood sample from a 28-year old Caucasian female subject
failed DNA extraction and thus her polymorphism status
could not be determined. We excluded her from the
genotype-stratified data. There was no difference inzygotes C allele carriers p value*
19a
(18e57) 29  7 (21e44) 1.00
37 0.18
90 0.03
16 0.61
0.78 (1.66e4.18) 3.51  0.84 (1.63e4.86) 0.07
(61e115) 88  13 (62e114) 0.64
1.11 (2.44e6.75) 4.69  1.01 (2.45e6.05) 0.08
(69e134) 98  13 (79e125) 0.87
32e11.47) 7.53 (5.44e10.42) 0.87
rs.
y genotyped. 19 C allele carriers include two homozygotes
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(Table 1).
Genotype status did not affect lack of response of
baseline FEV1 to CysLTR1 antagonism either at 2 h or at
three weeks. Two hours after montelukast, HS-PD20
increased by 64% (p Z 0.1928 compared with placebo) in
the A homozygotes, and by 57% in the C allele carriers
(p Z 0.0494 compared with placebo, p Z 0.6094 for the
difference between the genotypes). After three weeks of
montelukast, HS-PD20 increased by 84% in the A homozy-
gotes (p Z 0.0134 compared with placebo), and by 72% in
the C allele carriers (p Z 0.0250 compared with placebo,
p Z 0.5580 for the difference between the genotypes).Discussion
In this prospective, randomized, double-blind placebo-
controlled cross-over study, we found indirect evidence
that CysLTs mediate a significant proportion of the bron-
choconstrictor response in asthmatics after inhalation of
hypertonic saline. Further we found that three weeks
CysLTR1 antagonist therapy provides additional benefit in
terms of protection against this provocative stimulus.
Similar to exercise and cold air challenges, the presence
of a hyperosmolar environment stimulates inflammatory
cells in the airways such as epithelial cells, eosinophils,
basophils, mast cells and sensory nerve cells.1,20,21 Upon
activation, these cells release a variety of mediators
including histamine and acetylcholine.21e24 CysLTs are
unique arachidonic acid derived pro-inflammatory media-
tors which are purported to be released from resident
airway and inflammatory cells upon exposure of the bron-
chial epithelium to hyperosmolar stimuli. Mai et al.
demonstrated this by measuring elevated levels of urinary
LTE4 levels after HS inhalation challenges.
14 However, the
relative contribution of CysLTs to the pathophysiology of
the resultant bronchospasm was unknown. The 59% change
that we found in HS-PD20 after one dose of a CysLTR1
antagonist indicates both the qualitative and the relative
quantitative role that CysLTs play in HS-induced broncho-
spasm. This degree of bronchoprotection offered by mon-
telukast against HS-induced bronchospasm is similar to that
which it offers against exercise-induced bronchospasm.
Leff et al. demonstrated that twelve weeks of therapy with
montelukast led to a 47.4% improvement in the AUC (area
under the curve) of change in FEV1 as compared with
placebo (p Z 0.002).10 Similar degree of protection from
montelukast was observed in early response to allergen
challenges (53% improvement in post-challenge FEV1).
25 In
contrast, montelukast does not effect the airway sensitivity
to mannitol, but does improve recovery from the
challenge.26
The increased effect of CysLTR1 antagonism that we
noted after three weeks of administration is of interest.
Since montelukast has very high affinity for the CysLTR1,27 it
is unlikely that further receptor blockade occurs after
multiple doses. It is possible that the increased response
after three weeks is related to anti-inflammatory effects of
long term CysLTR1 antagonism.28 Prior reports have sup-
ported this as well. Seven day treatment with zafirlukast
(another CysLTR1 antagonist) was found to be associatedwith reduced number of lymphocytes and basophils and
indices of inflammation in BAL fluid after an antigen chal-
lenge.29 Montelukast therapy for four weeks has been shown
to reduce sputum and blood eosinophils in addition to
improving asthma control,30 while daily therapy with pran-
lukast (another CysLTR1 antagonist) therapy was associated
with significant decreases in mast cells, eosinophils and
T lymphocytes in endobronchial biopsy specimens.31
Variability in the prevalence of hyper-responsiveness to
hypertonic saline is attributed to the differences in severity
of asthma in the subjects studied, in the concentration of
HS used (3 or 4.5%) and the cut off for the drop in FEV1
required to define a positive challenge (15 or 20). We
suspect that our relatively high rate of screen failures may
have been due to the relatively dilute hypertonic saline
(3%) which we used. However, Leuppi et al. found that only
234 out of 604 asthmatics (99% with mild disease) i.e. 39%
achieved a PD15 to 4.5% hypertonic saline challenge.
32
54.8% of children with a diagnosis of asthma did not
demonstrate the prevalence of hyper-responsiveness to
4.5% saline when studied by Riedler et al.33 Thus, our data
are comparable to prior reports.
There are several reasons to believe that the LTC4S
promoter polymorphism might identify a subgroup of asth-
matics who would preferentially respond to CysLTR1
antagonists. The variant C allele is associated with
enhanced gene transcription and increased cellular
capacity for CysLT synthesis in a dominant manner.16,34
Sampson et al. demonstrated significantly increased LTC4
synthesis in stimulated eosinophils from C allele carriers.17
Further, in a study in 23 patients with severe asthma, there
was a trend toward greater response to 2 weeks of therapy
with zafirlukast in C allele carriers as compared to A
homozygotes. The C allele has also been associated with
decreased risk of asthma exacerbations18 - the authors
observed an 80% reduction in risk of asthma exacerbation in
C allele variants of the LTC4S polymorphism when compared
with the A homozygotes (p < 0.001) after six months of
montelukast therapy. We were unable to demonstrate
a difference in the acute or three-week response to mon-
telukast between the genotypes. It is likely that our study
was underpowered to detect a difference. Another expla-
nation for this observation is that the secondary effects of
prolonged CysLTR1 antagonism of decrease in the airway
inflammatory milieu referred to earlier28e31 overwhelm the
difference in genotype-specific CysLT release between the
two groups.
We did not find an effect of a single dose or a three-week
course of montelukast on baseline lung function in the
cohort as a whole or in the genotype-stratified analysis.
This contrasts with an open label trial of 4 week therapy
with the CysLTR1 antagonist pranlukast in moderate asth-
matics with a baseline FEV1 of 65% where a 14.3% increase
in FEV1 in C allele carriers occurred compared to a 3.1%
increase in A homozygotes (p < 0.01).19 The lack of
improvement in baseline lung function in our subjects may
have been due to the fact that we studied asymptomatic
asthmatics with an average baseline FEV1 of 87% (range
61e115%) of predicted and thus little improvement in FEV1
would have been expected.
To summarize, we found indirect evidence that cysteinyl
leukotrienes mediate a significant portion of the acute
672 S. Kazani et al.airway narrowing that occurs in response to hyperosmolar
stimuli. The degree of protection offered by a CysLTR1
antagonist in this setting is similar to that seen in response
to exercise and allergen-induced bronchoconstriction. The
bronchoprotection increases with three weeks of CysLTR1
antagonist therapy, possibly secondary to additional anti-
inflammatory or disease-modifying effects that occur with
prolonged CysLTR1 antagonism.
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